Groundbreaking study uncovers previously unknown benefits of losing weight
A groundbreaking study, published in the journal Nature, conducted the first highly detailed analysis of changes that weight loss causes in human fat tissue, examining hundreds of thousands of cells.
Beyond the cellular clearance, researchers also identified an increased metabolism of harmful fats.
These findings could pave the way for future therapies targeting conditions such as type 2 diabetes.
The research compared fat tissue samples from individuals of a healthy weight with those suffering from severe obesity (with a BMI over 35) who were undergoing bariatric weight loss surgery.
The weight loss cohort provided samples during surgery and again more than five months later, by which point they had lost an average of 25kg.
Researchers from the Medical Research Council (MRC) Laboratory of Medical Sciences in London, and from Imperial College London, analysed gene expression in more than 170,000 cells that made up the fat tissue samples, from 70 people.
They discovered that weight loss triggers the breakdown and recycling of fats called lipids.
This recycling process could be responsible for burning energy and reversing the harmful build-up of lipids in other organs like the liver and pancreas, they said.
Further research is now needed to work out if lipid recycling is linked to the positive effects of weight loss on health, such as remission of type 2 diabetes.
Scientists also found that the weight loss cleared out senescent cells, which are ageing and damaged cells that accumulate in all tissues.
These cells no longer function properly and release signals that lead to tissue inflammation and scarring.
'We've known for a long time that weight loss is one of the best ways to treat the complications of obesity, such as diabetes, but we haven't fully understood why,' Dr William Scott, who led the study, said.
'This study provides a detailed map of what may actually be driving some of these health benefits at a tissue and cellular level.
'Fat tissues have many under-appreciated health impacts, including on blood sugar levels, body temperature, hormones that control appetite, and even reproductive health.
'We hope that new information from studies like ours will start to pave the way for developing better treatments for diabetes and other health problems caused by excess body fat.'
Researchers found that weight loss did not, however, improve the effects of obesity on some aspects of the immune system.
Inflammatory immune cells, for example, did not fully recover even after weight loss.
Experts said this type of inflammatory cell memory could be harmful in the long term if people regain weight.
The study was funded by the Medical Research Council, Diabetes UK and Wellcome.
Dr Faye Riley, research communications lead at Diabetes UK, said: 'For some people, losing weight can put their type 2 diabetes into remission.
'But weight loss is challenging, and current approaches don't work for everyone.
'This research offers a rare window into the changes that occur in fat tissue during weight loss that may be key to improving health and putting type 2 diabetes into remission.
'By deepening our understanding of these processes, the study could open the door to innovative therapies that mimic the effects of weight loss, potentially helping people with type 2 diabetes to manage their condition or go into remission.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
44 minutes ago
- Medscape
Inflammatory Foods in Pregnancy Can Up T1D Risk in Kids
TOPLINE: Each 1-unit increase in the mother's dietary inflammation score during the middle of pregnancy was associated with a 16% higher risk for incident type 1 diabetes (T1D) in offsprings during their first 18 years of life. METHODOLOGY: Researchers in Denmark conducted a prospective study of 67,701 mother-child pairs drawn from a population-based cohort to investigate whether a proinflammatory maternal diet raised the offspring's risk for incident T1D. Maternal dietary intake was collected using a 360-item comprehensive food frequency questionnaire during gestational week 25 of pregnancy. The inflammatory potential of the maternal diet was assessed using an Empirical Dietary Inflammatory Index score, with higher or positive values denoting a more proinflammatory diet (red meats, dairy low fat, pizza, margarine, potatoes, low energy drink, and savoury snacks) and lower or negative values indicating an anti‐inflammatory diet (alliums, tomato, whole grain, coffee, green leafy vegetables, fruit juice, dark meat fish, tea, and natural fruits). Children were followed up for a mean duration of 17.58 years, and the diagnosis of T1D was confirmed through linked national health registries. TAKEAWAY: Among the 67,701 mother-child pairs, 0.42% of children developed T1D, with a median age at diagnosis of 10.2 years. Each 1-unit increase in the maternal Empirical Dietary Inflammatory Index score increased the risk for T1D in offsprings by 16% (hazard ratio [HR], 1.16; 95% CI, 1.02-1.32); this link between the proinflammatory diet and the risk for T1D was seen in both boys and girls. Maternal smoking throughout pregnancy was linked to a lower risk for T1D in offsprings (HR, 0.47); however, a diet high in gluten content was associated with an increased risk for T1D (HR per 10 g/d increase in gluten intake, 1.36). IN PRACTICE: "Collectively, [the study] findings add to the growing body of evidence suggesting that paediatric type 1 diabetes may be influenced by prenatal or early postnatal modifiable factors," the authors wrote. "Mid-pregnancy may be a critical period during which the fetus is particularly susceptible to maternal lifestyle influences," they added. SOURCE: This study was led by Rohina Noorzae, Statens Serum Institut, København, Denmark. It was published online on July 01, 2025, in the Journal of Epidemiology & Community Health. LIMITATIONS: This study was affected by unmeasured confounding factors, such as inflammatory properties of the children's own diets, which could not be ruled out. DISCLOSURES: This study was supported by the European Foundation for the Study of Diabetes/Juvenile Diabetes Research Foundation (JDRF)/Lilly Programme and JDRF. One author was supported by funding from the Novo Nordisk Foundation. The authors reported having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
44 minutes ago
- Yahoo
New 'groundbreaking' diabetes treatment trialled by NHS could delay insulin need
A revolutionary medication designed to slow the progression of type 1 diabetes is currently being tested by a small number of NHS patients across the UK. Teplizumab, which has already received approval in the United States, teaches the immune system to cease its assault on pancreatic cells, postponing the requirement for insulin by an average of three years. In type 1 diabetes, the body's immune system launches an attack on the insulin-producing cells within the pancreas, resulting in the loss of natural blood sugar regulation. When blood glucose levels become excessively high or dangerously low, it can lead to severe health complications and potentially prove fatal. Individuals diagnosed with type 1 diabetes consequently require daily insulin injections. READ MORE: NHS says 'contact your GP practice' if you notice symptom that 'could be cancer' READ MORE: Preeclampsia may reduce lifelong risk of multiple cancers up to 45%, new study finds Hannah Robinson, a 36-year-old dentist and mother of two from Devon, has become the first adult in the UK to trial the medication in hopes of delaying the onset of her condition. She is receiving care at the Royal Devon University Healthcare NHS Foundation Trust following the discovery during her pregnancy that she was in the preliminary stages of developing type 1 diabetes. A small group of individuals are receiving the treatment on an individual assessment basis whilst it undergoes evaluation for broader NHS implementation. She explained: "For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. "This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. "This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this." Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: "This new treatment represents a really exciting shift in how we manage type 1 diabetes. "For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. "Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. "My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all." Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: "For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. "Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. "That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. "Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes." Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, commented: "Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. "It is really important to find new and improved approaches for identifying individuals at elevated risk."
Yahoo
an hour ago
- Yahoo
Charley Hull twice collapses, carted off after Evian WD
After a few scary moments, Charley Hull withdrew from the Amundi Evian Championship on Thursday. The 29-year-old Hull was carted off just three holes into her opening round at Evian Resort in France with what broadcasters were describing as a virus. Earlier in her round, Hull was shown sitting down near a bunker on the third hole. She then reportedly collapsed twice on the fourth tee. Advertisement Hull received treatment during a 15-minute medical break before she attempted to hit her tee shot on the fourth hole, after which she collapsed for the second time. That's when Hull called it quits. Hull's withdrawal ends a nice run by the world No. 19 in majors, in which she has posted back-to-back T-12 finishes, at the U.S. Women's Open and KPMG Women's PGA. She was third at the 2022 Evian.
